Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting Treatment Outcome in Major Depressive Disorder
NCT02869035Phase 1Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of escitalopram in major depressive disorder (MDD) (3 arms), sponsored by Rigshospitalet. Primary endpoints: Remission from depression at 8 weeks, Cerebral 5-HT4R binding at 8 weeks and 9 more. Started Aug 2016; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02869035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869035.